Table 1.

Baseline patient demographics and clinical characteristics

CP-870,893 Dose cohort
0.1 mg/kg (n = 3)0.2 mg/kg (n = 6)MTD expansion 0.2 mg/kg (n = 13)
Characteristicn (%)n (%)n (%)
Age, y
 Median5959
 Range57–7240–81
Sex
 Male2 (67)3 (50)9 (69)
 Female1 (33)3 (50)4 (31)
Race/ethnicity
 White0 (0)5 (83)11 (84)
 Black3 (100)1 (17)1 (8)
 Asian0 (0)0 (0)1 (8)
ECOG PS
 02 (67)5 (83)2 (15)
 11 (33)1 (17)11 (85)
Extent of disease
 Locally advanced0 (0)0 (0)2 (15)
 Metastatic3 (100)6 (100)11 (85)
Location of primary
 Head2 (67)2 (33)4 (31)
 Body or tail1 (33)2 (33)9 (69)
 Not reported0 (0)2 (33)0 (0)
Site of metastases
 Liver3 (100)5 (83)10 (77)
 Lung0 (0)2 (33)0 (0)
 Peritoneal0 (0)0 (0)3 (23)
 Skeleton0 (0)2 (33)0 (0)
 Other0 (0)0 (0)1 (8)
Prior radiotherapies
 No3 (100)6 (100)11 (84)
 Yes0 (0)0 (0)1 (8)
 Not reported0 (0)0 (0)1 (8)